Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Baeten, Dominique; Østergaard, Mikkel; Cheng‐Chung Wei, James; Sieper, Joachim; A. Järvinen, Pentti; Tam, Lai‐Shan; Salvarani, Carlo; Kim, Tae‐Hwan; M. Solinger, Alan; Datsenko, Yakov; Pamulapati, Chandrasena; Visvanathan, Sudha; B. Hall, David; Aslanyan, Stella; Scholl, Paul; J. Padula, Steven

doi:10.1136/annrheumdis-2018-213328

Public

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Published in Annals of the Rheumatic Diseases • Aug 10, 2018

Authors:

Dominique Baeten

Mikkel Østergaard

James Cheng‐Chung Wei

Abstract

OBJECTIVES: To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS). METHODS: A total of 159 patients with biological-naïve AS, with active disease (Bath Ankylosing S...

Subject

Medicine

Ankylosing spondylitis

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!